Leucovorin + Irinotecan Hydrochloride Interaction
Moderateinteraction on record
Description
Co-administration with 5-FU reduces SN-38 Cmax by 14% and AUC by 8%. This sequence is recommended in combination trials.
Mechanism
Reduced active metabolite exposure when irinotecan followed by 5-FU and leucovorin
Source: NLP:irinotecan hydrochloride